Business Description
Medigene AG
ISIN : DE000A40ESG2
Share Class Description:
WBO:MDG2: Namen-Akt. nach KapitalherabsetzungCompare
Compare
Traded in other countries / regions
MDG1.Germany0QGJ.UKMDG2.AustriaMDG1.SwitzerlandMDGEF.USA IPO Date
2017-09-04Description
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.51 | |||||
| Equity-to-Asset | 0.68 | |||||
| Debt-to-Equity | 0.13 | |||||
| Debt-to-EBITDA | -0.18 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -21.29 | |||||
| Beneish M-Score | -3.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -9 | |||||
| 3-Year EBITDA Growth Rate | 12.2 | |||||
| 3-Year EPS without NRI Growth Rate | 17.6 | |||||
| 3-Year FCF Growth Rate | 14.5 | |||||
| 3-Year Book Growth Rate | -26.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 23.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 32.46 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 1.25 | |||||
| 9-Day RSI | 7.46 | |||||
| 14-Day RSI | 17.3 | |||||
| 6-1 Month Momentum % | -29.6 | |||||
| 12-1 Month Momentum % | -40.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.39 | |||||
| Quick Ratio | 2.39 | |||||
| Cash Ratio | 2.15 | |||||
| Days Sales Outstanding | 36.76 | |||||
| Days Payable | 133.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 3.68 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 79.94 | |||||
| Operating Margin % | -207.04 | |||||
| Net Margin % | -213.98 | |||||
| FCF Margin % | -300.73 | |||||
| ROE % | -67.4 | |||||
| ROA % | -46.54 | |||||
| ROIC % | -73.96 | |||||
| 3-Year ROIIC % | -25.37 | |||||
| ROC (Joel Greenblatt) % | -272.08 | |||||
| ROCE % | -55.27 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.59 | |||||
| PB Ratio | 1.12 | |||||
| Price-to-Tangible-Book | 2.22 | |||||
| EV-to-EBIT | -0.69 | |||||
| EV-to-Forward-EBIT | -0.73 | |||||
| EV-to-EBITDA | -0.76 | |||||
| EV-to-Forward-EBITDA | -0.73 | |||||
| EV-to-Revenue | 1.42 | |||||
| EV-to-Forward-Revenue | 1.05 | |||||
| EV-to-FCF | -0.47 | |||||
| Price-to-Median-PS-Value | 0.28 | |||||
| Price-to-Net-Current-Asset-Value | 3.43 | |||||
| Price-to-Net-Cash | 4.57 | |||||
| Earnings Yield (Greenblatt) % | -144.93 | |||||
| FCF Yield % | -101.7 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Medigene AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 7.446 | ||
| EPS (TTM) (€) | -1.213 | ||
| Beta | 0.37 | ||
| Volatility % | 54.08 | ||
| 14-Day RSI | 17.3 | ||
| 14-Day ATR (€) | 0.049061 | ||
| 20-Day SMA (€) | 1.8431 | ||
| 12-1 Month Momentum % | -40.59 | ||
| 52-Week Range (€) | 1.508 - 5.115385 | ||
| Shares Outstanding (Mil) | 14.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Medigene AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Medigene AG Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Medigene AG Frequently Asked Questions
What is Medigene AG(WBO:MDG2)'s stock price today?
The current price of WBO:MDG2 is €1.51. The 52 week high of WBO:MDG2 is €5.12 and 52 week low is €1.51.
When is next earnings date of Medigene AG(WBO:MDG2)?
The next earnings date of Medigene AG(WBO:MDG2) is 2025-03-28 Est..
Does Medigene AG(WBO:MDG2) pay dividends? If so, how much?
Medigene AG(WBO:MDG2) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers